Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (2)
  • 1
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 19, No. 5 ( 2013-03-01), p. 1126-1138
    Abstract: Purpose: Anti-EGF receptor (EGFR) antibodies and small-molecule tyrosine kinase inhibitors have shown activity in epithelial tumors; however, agents that work by blocking the EGFR growth signal are ineffective when the oncogenic stimulus arises downstream, such as in tumors with KRAS mutations. Antibodies of the IgG1 subclass can also kill tumor cells directly through antibody-dependent cell-mediated cytotoxicity (ADCC), and the efficacy of this is determined by the interaction of the Fc portion of the target cell–bound antibody and Fc receptors present on immune effector cells. Experimental Design: We report the development of GA201, a novel anti-EGFR monoclonal antibody with enhanced ADCC properties. GA201 was derived by humanization of the rat ICR62 antibody. The Fc region of GA201 was glycoengineered to contain bisected, afucosylated carbohydrates for enhanced binding to FcγRIIIA. Results: In vitro binding of GA201 to EGFR inhibited EGF ligand binding, EGFR/HER2 heterodimerization, downstream signaling, and cell proliferation to a similar extent as cetuximab. However, GA201 exhibited superior binding to both the low- and high-affinity variants of FcγRIIIA. This resulted in significantly enhanced induction of ADCC compared with cetuximab against both KRAS-wild-type and -mutant tumor cells lines. This enhanced ADCC translated into superior in vivo efficacy in a series of mouse xenograft models. Efficacy of GA201 was further increased when administered in combination with chemotherapy (irinotecan). Conclusions: These data suggest that GA201 may be more effective than cetuximab in patients with EGFR-positive solid tumors and may also represent a first-in-class treatment of patients with KRAS-mutated tumors. Clin Cancer Res; 19(5); 1126–38. ©2012 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 8_Supplement ( 2010-04-15), p. 1058-1058
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 1058-1058
    Abstract: Mutations in the gene encoding the cell adhesion molecule E-cadherin and overexpression of the epidermal growth factor receptor (EGFR) represent fundamental genetic alterations associated with diffuse-type gastric cancer. Mutations, e.g. in frame deletion of exon 8 (del 8), lead to loss of putative extracellular Ca2+-binding sites of E-cadherin, thereby impairing its functionality. Several studies have shown a bidirectional crosstalk between E-cadherin and EGFR. Functional wild-type (wt) E-cadherin inhibits ligand-induced EGFR activation, but mutations lead to a loss of its suppressive function, resulting in increased EGFR activation and recruitment of downstream signalling components. The phenotype of cells harboring such mutations is characterized by increased proliferation and elevated migratory and invasive potential. Our project aims at studying the impact of somatic mutations of E-cadherin on EGFR-mediated signalling pathways, in order to identify signalling molecules of these pathways as molecular targets for selective therapies in gastric cancer. Cell lines expressing wt or mutant E-cadherin (del 8) were EGF-stimulated and cellular lysates were analyzed by commercial proteome profiler antibody array (R & D Systems). The array allowed detection of the phosphorylation status of 48 signalling molecules and facilitated identification of differential activation. We found differential response to EGF stimulation of proteins involved in DNA damage and repair, such as p53 and CHK2, in both cell lines. As both proteins are tumorsuppressors, their dysfunction could contribute to tumor progression. Furthermore, Src-family kinases (SFKs) like Src, Yes, Fgr, Lck and Lyn exhibited different activation profiles in response to EGF-stimulation in both cell lines. As SFKs are key players in multiple cellular processes like cell growth, differentiation, cellular adhesion, migration and invasion, the impact of their differential activation on the cellular phenotype is subject of ongoing experiments. To determine the role of the identified targets in gastric carcinogenesis and the mechanisms of crosstalk between E-cadherin and EGFR a protein microarray platform was established, allowing analysis of multiple samples under the same experimental conditions. This approach will reveal new insights in EGFR-mediated signalling pathways contributing to gastric carcinogenesis and complete our data describing how tumor associated mutations of E-cadherin affect cellular signalling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1058.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages